You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The companies are positioning the test, called SeptiCyte Rapid, for use in triaging COVID-19 patients who could be at greater risk for progressing to sepsis.
The company's RaPID platform detects infections directly from a blood sample and can provide results in three hours.
The firm reissued its full-year guidance and said it expects to sell 60 instruments in the US for the remainder of the year.
Sepset said its early test for sepsis, a condition that requires rapid diagnosis and treatment, would give clinicians valuable time to identify treatment strategies.
The Lexington, Massachusetts-based company has launched a two-hour SARS-CoV-2 test on its fully-automated instrument, the T2Dx.
The firm expects to validate its test as a triage tool to identify SARS-CoV-2 patients at risk of sepsis and pursue US FDA Emergency Use Authorization.
In December the firm won $4 million from CARB-X to support the platform's first test identifying the most common bloodstream infections associated with sepsis.
British bioinformatics firm PrecisionLife has mined the UK Biobank to identify genetic risk factors for late-stage COVID-19 patients developing sepsis.
DNAe said its semiconductor-based platform has potential to detect a broader variety of pathogens and resistance genes than current molecular technologies.
The Boston-based firm is developing a bacterial diagnostic platform to detect antibiotic resistance and help guide antibiotic treatment in hospitals.
President Donald Trump might not approve the stricter standards the US Food and Drug Administration is developing for authorizing a SARS-CoV-2 vaccine, according to Politico.
Wired reports that Oxitec has now developed a genetically modified fall armyworm.
A large genetic study finds SARS-CoV-2 viruses with a certain variant are spreading more than others, according to the Washington Post.
In Nature this week: sister-chromatid-sensitive chromosome conformation capture approach, and more.